Quest Diagnostics (DGX) director boosts holdings with small dividend reinvestment

Rhea-AI Filing Summary

Quest Diagnostics director Wright Lassiter III reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 6 shares of common stock at $194.699 per share, bringing his direct holdings to 9,063 shares after the transaction. The filing notes this dividend reinvestment transaction is eligible for deferred reporting under Rule 16a-6, but the director chose to report it early on Form 4.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lassiter Wright III

Role null

Type	Security	Shares	Price	Value
L	Common Stock	6	$194.699	$1K

Holdings After Transaction: Common Stock — 9,063 shares (Direct, null)

Footnotes (1)

1. Represents an award of restricted share units. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Key Figures

Shares acquired: 6 shares Price per share: $194.699 per share Shares held after transaction: 9,063 shares

3 metrics

Shares acquired 6 shares Common stock acquired on April 20, 2026

Price per share $194.699 per share Acquisition price for the 6 shares

Shares held after transaction 9,063 shares Direct common stock ownership after acquisition

Key Terms

dividend reinvestment plan, Rule 16a-6, restricted share units

3 terms

dividend reinvestment plan financial

"shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

restricted share units financial

"Represents an award of restricted share units."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lassiter Wright III

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	04/20/2026		L	V	6(2)	A	$194.699	9,063	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted share units.

2. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Wright L. Lassiter, III	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Quest Diagnostics (DGX) report for Wright Lassiter III?

Quest Diagnostics director Wright Lassiter III reported a small stock acquisition. He obtained 6 shares of common stock via a dividend reinvestment plan at $194.699 per share, increasing his direct holdings to 9,063 shares after the transaction.

How many Quest Diagnostics (DGX) shares does Wright Lassiter III hold after this Form 4?

After the reported transaction, Wright Lassiter III directly holds 9,063 Quest Diagnostics common shares. This reflects the addition of 6 shares acquired on April 20, 2026 through a dividend reinvestment plan, as disclosed in the Form 4 filing.

What was the price per share in the latest Quest Diagnostics (DGX) insider acquisition?

The latest reported acquisition was priced at $194.699 per share. Director Wright Lassiter III acquired 6 Quest Diagnostics common shares at this price through a dividend reinvestment plan, according to the Form 4 insider transaction disclosure.

What does Rule 16a-6 mean in the Quest Diagnostics (DGX) Form 4 filing?

Rule 16a-6 allows certain small acquisitions, such as dividend reinvestment plan purchases, to be reported later on Form 5. In this case, the Quest Diagnostics director chose to report the eligible transaction early on Form 4 instead of deferring disclosure.

Was the Quest Diagnostics (DGX) insider transaction an open-market purchase or a plan reinvestment?

The disclosed transaction was a plan reinvestment, not an open-market trade. The 6 shares of Quest Diagnostics common stock were acquired through a dividend reinvestment plan administered by the director’s broker, as described in the Form 4 footnotes.